EA201001640A1 - PHARMACEUTICAL ANTIBACTERIAL COMPOSITION BASED ON NANOPARTICLES CYCLODEXTRIN CONTAINING ANTIBIOTIC FROM RIFAMYCIN GROUP, METHOD FOR ITS PRODUCTION AND METHOD - Google Patents
PHARMACEUTICAL ANTIBACTERIAL COMPOSITION BASED ON NANOPARTICLES CYCLODEXTRIN CONTAINING ANTIBIOTIC FROM RIFAMYCIN GROUP, METHOD FOR ITS PRODUCTION AND METHODInfo
- Publication number
- EA201001640A1 EA201001640A1 EA201001640A EA201001640A EA201001640A1 EA 201001640 A1 EA201001640 A1 EA 201001640A1 EA 201001640 A EA201001640 A EA 201001640A EA 201001640 A EA201001640 A EA 201001640A EA 201001640 A1 EA201001640 A1 EA 201001640A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pharmaceutically acceptable
- nanoparticles
- forms
- acceptable carrier
- antibiotic
- Prior art date
Links
Abstract
Изобретение относится к медицине и фармации, а именно к фармацевтической композиции для лечения микобактериозов и геликобактерной инфекции, на основе диспергированных в фармацевтически приемлемом носителе наночастиц циклодекстрина размером от 100 до 1000 нм, содержащих терапевтически эффективное количество диспергированного в них антибиотика из группы рифамицинов (предпочтительно рифабутина), а также фармацевтически приемлемые вспомогательные вещества, отличающейся тем, что указанные наночастицы не содержат полимера, к способу получения (синтеза) указанной фармацевтической композиции, а также к способам лечения микобактериозов и геликобактерной инфекции, включающим внутривенное, и/или внутримышечное, и/или пероральное введение нуждающемуся в этом пациенту указанной композиции (в виде суспензии в фармацевтически приемлемом носителе) в терапевтически эффективном количестве. Композиция в соответствии с изобретением может быть выполнена как в виде лиофилизата, пригодного (после диспергирования в фармацевтически приемлемом носителе) для внутривенного или внутримышечного введения пациенту, так и в виде порошка, пригодного для изготовления твердых пероральных лекарственных форм, и обеспечивает эффективность не менее (а в ряде случаев - и более) высокую, чем традиционные пероральные формы рифабутина (капсулы), и лишена недостатков как существующих традиционных пероральных форм, так и известных наносомальных (коллоидных) форм данного антибиотика.The invention relates to medicine and pharmacy, in particular to a pharmaceutical composition for the treatment of mycobacteriosis and helicobacter infection, based on cyclodextrin nanoparticles from 100 to 1000 nm dispersed in a pharmaceutically acceptable carrier, containing a therapeutically effective amount of a rifamycin (preferably rifabutin) antibiotic dispersed in them as well as pharmaceutically acceptable excipients, characterized in that the said nanoparticles do not contain a polymer, to the method of obtaining (synthesis) of the specified pharmaceutical composition, as well as to methods for treating mycobacteriosis and helicobacter infection, including intravenous and / or intramuscular and / or oral administration to the patient in need of the specified composition (as a suspension in a pharmaceutically acceptable carrier) in a therapeutically effective amount . The composition in accordance with the invention can be performed both as a lyophilisate, suitable (after dispersing in a pharmaceutically acceptable carrier) for intravenous or intramuscular administration to a patient, or as a powder suitable for making solid oral dosage forms, and provides efficacy no less ( in some cases - and more) higher than traditional oral forms of rifabutin (capsules), and is free from the drawbacks of both existing traditional oral forms and known nanosomal ( loidnyh) forms of the antibiotic.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201001640A EA016410B1 (en) | 2010-11-13 | 2010-11-13 | Pharmaceutical composition based on cyclodextrin nanoparticles comprising rifabutin, method for preparing thereof, method for treating mikobacteriosis and helicobacterial infection (variants) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201001640A EA016410B1 (en) | 2010-11-13 | 2010-11-13 | Pharmaceutical composition based on cyclodextrin nanoparticles comprising rifabutin, method for preparing thereof, method for treating mikobacteriosis and helicobacterial infection (variants) |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201001640A1 true EA201001640A1 (en) | 2012-03-30 |
EA016410B1 EA016410B1 (en) | 2012-04-30 |
Family
ID=45908240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201001640A EA016410B1 (en) | 2010-11-13 | 2010-11-13 | Pharmaceutical composition based on cyclodextrin nanoparticles comprising rifabutin, method for preparing thereof, method for treating mikobacteriosis and helicobacterial infection (variants) |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA016410B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113015519A (en) * | 2019-09-12 | 2021-06-22 | 生物验证系统股份公司 | Rifabutin treatment methods, uses and compositions |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11344537B2 (en) | 2019-09-18 | 2022-05-31 | BioVersys AG | Rifabutin treatment methods, uses, and compositions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL149030A0 (en) * | 2000-08-09 | 2002-11-10 | Panacea Biotec Ltd | Pharmaceutical compositions containing rifampicin, isoniazid or combinations thereof |
ES2310122B1 (en) * | 2007-04-20 | 2009-10-30 | Instituto Cientifico Y Tecnologico De Navarra, S.A | NANOPARTICLES THAT INCLUDE A CYCLODEXTRINE AND A BIOLOGICALLY ACTIVE MOLECULA AND ITS APPLICATIONS. |
EA200801388A1 (en) * | 2008-06-20 | 2009-08-28 | Ооо «Нпк "Наносистема"» | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUBERCULOSIS AND DISEASES MEDIATED BY HELICOBACTER PILORY BASED ON POLYMERIC NANOPARTICLES, ITS TREATMENT METHOD AND TREATMENT METHOD |
-
2010
- 2010-11-13 EA EA201001640A patent/EA016410B1/en active IP Right Revival
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113015519A (en) * | 2019-09-12 | 2021-06-22 | 生物验证系统股份公司 | Rifabutin treatment methods, uses and compositions |
Also Published As
Publication number | Publication date |
---|---|
EA016410B1 (en) | 2012-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2010140682A (en) | METHOD FOR TREATING PATIENTS FROM INFECTION, PHARMACEUTICAL COMPOSITION (OPTIONS) AND MEDICINE | |
EA201492010A1 (en) | APPLICATION OF HIGH DOSE OF LACHINIMODE FOR TREATMENT OF MULTIPLE SCLEROSIS | |
EA201590836A1 (en) | COMPOSITIONS WITH LOW DOSE OF PANCRELIPASE AND INTESTINAL COATING | |
EA201690069A1 (en) | THE USE OF HIGH DOSE PRIDOPIDINE FOR THE TREATMENT OF THE HANTINGTON'S DISEASE | |
NZ621433A (en) | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use | |
EA201270221A1 (en) | TREATMENT OF CROWN DISEASE WITH LACQUINIMODE | |
RU2013148732A (en) | COMBINATIONS OF COMPOUNDS INHIBITING ACT AND CHEMOTHERAPEUTIC AGENTS AND WAYS OF THEIR APPLICATION | |
WO2012007159A3 (en) | Novel gastro-retentive dosage forms | |
RU2013156378A (en) | 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1h-benzimidazole-2-yl] -1h-quinolin-2-one for use in the treatment of adenocystic carcinoma | |
NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
RU2010132581A (en) | METHODS FOR LUNG DISEASES THERAPY | |
RU2013127420A (en) | WAYS TO REDUCE PSYCHOGENIC OR COMPULSIVE Overeating | |
MX2022012351A (en) | Co-administration of mirdametinib and lifirafenib for use in treating cancers. | |
RU2017113354A (en) | INJECTION MICROPARTICLES FOR SUPERLOCALIZED RELEASE OF THERAPEUTIC MEDICINES | |
HRP20210418T1 (en) | Syd985 treatment of t-dm1 refractory cancer patients | |
JP2016512247A5 (en) | ||
MX2013003523A (en) | Low dose pharmaceutical composition comprising zanamivir. | |
RU2012108144A (en) | ANTI-CANCER THERAPY DIRECTED AGAINST CANCER STEM CELLS AND CANCER FORMS RESISTANT TO TREATMENT BY MEDICINES | |
EA201001640A1 (en) | PHARMACEUTICAL ANTIBACTERIAL COMPOSITION BASED ON NANOPARTICLES CYCLODEXTRIN CONTAINING ANTIBIOTIC FROM RIFAMYCIN GROUP, METHOD FOR ITS PRODUCTION AND METHOD | |
JP2010106019A (en) | Agent of prophylaxis, therapy, and or symptom alleviation for peripheral neuropathy resulting from cancer chemotherapy comprising limaprost | |
RU2013105513A (en) | Derivatives of 1-aminoalkylcyclohexane for the treatment of inflammatory skin diseases | |
EA200900214A1 (en) | PHARMACEUTICAL COMPOSITION OF RIFABUTIN FOR THE TREATMENT OF TUBERCULOSIS, THE WAY OF ITS OBTAINING AND THE METHOD OF TREATMENT | |
MX2010006310A (en) | O-desmethyl-venlafaxine for treating major depressive disorder. | |
WO2022021786A1 (en) | Tsl-1502 compound pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AZ BY KZ |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |
|
NF4A | Restoration of lapsed right to a eurasian patent |
Designated state(s): RU |
|
PC4A | Registration of transfer of a eurasian patent by assignment |